Respiratory Disease in Italy



Introduction

The IRC, a coalition of respiratory clinicians, patients and industry partners, aims to transform post-pandemic respiratory care and reduce mortality by a third globally by 2030 - in line with the UN Sustainable Development Goals.

The IRC is calling on governments and policy makers to establish funded national strategies, which include prevention, new models of care, ambitious measurable targets, and accountable leadership to improve lung health by focusing on:

Better...

- Prevention of respiratory diseases
- Access to the right treatment at the right time
- Action on reducing inequalities
- Prioritisation of research, data and insight to improve care

The National Prevention Plan (PNP) 2020-2025 is a key tool for Italy's health strategy and aims to improve public health through prevention and wellness promotion interventions. It is a strategic initiative to improve public health and respiratory health. The plan focuses on six key objectives, with a particular focus on chronic respiratory diseases, part of non-transmissible diseases. Thanks to a multidisciplinary and lifelong approach, the focus is on the prevention and effective management of these diseases.

The IRC welcomes this strategy and is committed to working with all stakeholders to contribute to and promote respiratory health in Italy.

Societal economic cost by disease:







Asthma €2.8 billion €14.5 billion

Lung Cancer €21.3 billion



Lower respiratory tract infections €4.2 billion



Mesothelioma



Tuberculosis €976.4 million €176.3 million




Interstitial lung disease €1.8 billion



COVID-19 €34.3 billion



Pulmonary arterial hypertension €83.9 million



thousand deaths from respiratory diseases



healthy life years lost to respiratory diseases





This initiative is made possible with the contributions of the partner organisations who all support the IRC's goals: Expertise and time were provided by the European Respiratory Society, European Lung Foundation and Global Allergy and Airways Patient Platform; funding, expertise and time were contributed by AstraZeneca, Chiesi Group, GSK, Sanofi and Regeneron; additional funding was provided by Boehringer Ingelheim.